Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Scholar Rock Holding Corporation before investing.

In this article, we go over a few key elements for understanding Scholar Rock Holding Corporation’s stock price such as:

• Scholar Rock Holding Corporation’s current stock price and volume
• Why Scholar Rock Holding Corporation’s stock price changed recently
• Upgrades and downgrades for SRRK from analysts
• SRRK’s stock price momentum as measured by its relative strength

About Scholar Rock Holding Corporation (SRRK)

Before we jump into Scholar Rock Holding Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Scholar Rock Holding Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Scholar Rock Holding Corporation.

Scholar Rock Holding Corporation’s Stock Price as of Market Close

As of May 14, 2026, 10:17 AM, CST, Scholar Rock Holding Corporation’s stock price was $50.035.

Scholar Rock Holding Corporation is down 0.27% from its previous closing price of $50.170.

During the last market session, Scholar Rock Holding Corporation’s stock traded between $48.485 and $50.470. Currently, there are approximately 127.28 million shares outstanding for Scholar Rock Holding Corporation.

Scholar Rock Holding Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Scholar Rock Holding Corporation Stock Price History

Scholar Rock Holding Corporation’s (SRRK) price is currently up 7.35% so far this month.

During the month of May, Scholar Rock Holding Corporation’s stock price has reached a high of $50.470 and a low of $45.000.

Over the last year, Scholar Rock Holding Corporation has hit prices as high as $51.625 and as low as $27.070. Year to date, Scholar Rock Holding Corporation’s stock is up 13.59%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Scholar Rock Holding Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 13, 2026, there were analysts who downgraded Scholar Rock Holding Corporation’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Scholar Rock Holding Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Scholar Rock Holding Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Scholar Rock Holding Corporation (SRRK) by visiting AAII Stock Evaluator.

Relative Price Strength of Scholar Rock Holding Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 13, 2026, Scholar Rock Holding Corporation has a weighted four-quarter relative price strength of 6.59%, which translates to a Momentum Score of 76 and is considered to be Strong.

Want to learn more about how Scholar Rock Holding Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Scholar Rock Holding Corporation Stock Price: Bottom Line

As of May 14, 2026, Scholar Rock Holding Corporation’s stock price is $50.035, which is down 0.27% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Scholar Rock Holding Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.